NeoGenomics (NEO) AI Stock Analysis

• Market Cap: $785.41M
• Dividend Yield: N/A
• Average Volume (3M): 2.43M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: 9.70%
• EPS Growth: -30.94%
• Country: US
• Employees: 2,200
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.03
• Shares Outstanding: 129,178,620
• 10 Day Avg. Volume: 4,323,325
• 30 Day Avg. Volume: 2,433,920
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.51
• Enterprise Value/Revenue: 1.72
• Enterprise Value/Gross Profit: 3.91
• Enterprise Value/Ebitda: -24.41
• 1Y Price Target: $8.81
• Price Target Upside: 41.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12

• Rating: 44 Neutral
• Price Target: $5.50 ▼(-11.86% Downside)

The overall stock score reflects NeoGenomics' revenue growth and strategic board appointment but is heavily weighed down by ongoing profitability and cash flow issues, technical bearish signals, and valuation concerns.

Positive Factors

Clinical Performance

Underlying clinical performance was solid in the quarter, and sequential AUP improvement was strong.

Core Clinical Revenue

Core clinical revenues beat expectations, and any PanTracer contribution leaves room for upside.

Negative Factors

Delayed Product Launch

A delay in the commercial launch of PanTracer™ Liquid Biopsy impacted the expected NGS revenue ramp.

Guidance Cut

NEO shares are down due to a larger than expected guidance cut for FY25.

Non-Clinical Segment

Total revenue missed guidance and consensus due entirely to further headwinds in the 'non-clinical' business.

NeoGenomics Business Overview & Revenue Model

Company Description

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

How the Company Makes Money

NeoGenomics generates revenue primarily through its laboratory services, which include various cancer testing and diagnostic assays. The company charges healthcare providers, including hospitals and oncologists, for each test conducted. Key revenue streams include molecular testing, which encompasses a wide array of genetic and genomic tests, and anatomic pathology services. Additionally, NeoGenomics collaborates with pharmaceutical companies for clinical trial testing, providing another revenue source through partnerships. The company's focus on expanding its test menu and enhancing its capabilities in precision medicine contributes to its earnings, along with its strategic partnerships with healthcare institutions and research organizations.

NeoGenomics Financial Statement Overview

Summary

NeoGenomics shows strong revenue growth but is challenged by persistent negative EBIT and net income. Positive cash flow from operations is a strength, but the high debt-to-equity ratio and negative free cash flow indicate financial vulnerabilities. Strategic management is needed to enhance profitability and cash flow.

Income Statement

NeoGenomics has shown a steady increase in total revenue over recent years, with a TTM revenue of $672 million, indicating a growth trajectory. However, persistent negative EBIT and net income indicate ongoing profitability challenges, with negative margins across gross, EBIT, and net profit. The company needs to focus on cost management and operational efficiency to achieve profitability.

Balance Sheet

The company maintains a healthy equity ratio with stockholders' equity representing a significant portion of total assets. However, the debt-to-equity ratio remains elevated, reflecting a reliance on debt financing. Positive equity growth is a strength, but the high leverage poses potential risks, particularly given the current lack of profitability.

Cash Flow

Operating cash flow remains positive in the TTM, an improvement from previous periods, although free cash flow is still negative due to high capital expenditures. The company has shown improvement in cash management, but achieving positive free cash flow is critical for long-term sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	660.57M	591.64M	509.73M	484.33M	444.45M
Gross Profit	290.10M	244.60M	187.90M	187.06M	185.89M
EBITDA	-1.51M	-17.61M	-82.33M	-65.40M	34.85M
Net Income	-78.73M	-87.97M	-144.25M	-8.35M	4.17M
Balance Sheet
Total Assets	1.64B	1.68B	1.74B	1.87B	988.33M
Cash, Cash Equivalents and Short-Term Investments	386.84M	415.20M	437.99M	515.39M	296.26M
Total Debt	605.33M	611.68M	610.93M	612.79M	218.22M
Total Liabilities	735.70M	739.69M	742.01M	761.50M	294.04M
Stockholders Equity	902.34M	941.54M	998.02M	1.11B	694.29M
Cash Flow
Free Cash Flow	-34.04M	-30.70M	-96.88M	-90.86M	-27.64M
Operating Cash Flow	7.02M	-1.95M	-65.99M	-26.72M	1.46M
Investing Cash Flow	12.86M	76.71M	517.00K	-632.37M	-159.44M
Financing Cash Flow	4.65M	4.55M	11.83M	725.28M	235.60M

NeoGenomics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEO, the sentiment is Neutral. The current price of 6.24 is above the 20-day moving average (MA) of 5.91, below the 50-day MA of 6.74, and below the 200-day MA of 11.05, indicating a neutral trend. The MACD of -0.27 indicates Negative momentum. The RSI at 51.08 is Neutral, neither overbought nor oversold. The STOCH value of 92.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NEO.

NeoGenomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLGT	60 Neutral	$643.10M	―	-4.54%	―	4.31%	69.57%
MYGN	56 Neutral	$561.06M	―	-70.03%	―	3.83%	-137.31%
CDNA	56 Neutral	$663.21M	12.20	20.73%	―	14.72%	―
CSTL	56 Neutral	$561.02M	30.59	-2.15%	―	20.40%	-165.41%
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%
NEO	44 Neutral	$785.41M	―	-11.76%	―	9.70%	-30.94%
OPK	44 Neutral	$1.05B	―	-13.16%	―	-7.31%	29.84%

NeoGenomics Corporate Events

NeoGenomics Board Member Elizabeth Floegel Resigns

On August 5, 2025, Elizabeth Floegel resigned from the Board of Directors of NeoGenomics, Inc., effective immediately. Her resignation was not due to any disagreements with the company’s operations, policies, or practices.

The most recent analyst rating on (NEO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.

NeoGenomics Expands Board, Appoints New Director

On June 19, 2025, NeoGenomics, Inc. expanded its Board of Directors from nine to ten members and appointed Marjorie C. Green as a new director. Dr. Green, who is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck, brings extensive experience in oncology and business development. Her appointment is expected to enhance NeoGenomics’ strategic direction in the precision oncology market, aligning with the company’s mission to improve patient care.

The most recent analyst rating on (NEO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.

NeoGenomics Approves Key Proposals at Annual Meeting

On May 22, 2025, NeoGenomics, Inc. held its annual stockholders meeting where several key proposals were approved. These included an amendment to the 2023 Equity Incentive Plan, which increased the number of shares authorized for issuance and established a minimum vesting period, among other changes. Additionally, the election of nine directors to the Board and the approval of executive compensation were confirmed. The stockholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accountant.

The most recent analyst rating on (NEO) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.